The role of norepinephrine in the behavioral and psychological symptoms of dementia

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 16, Issue 3, 2004, Pages 261-276

  Herrmann, Nathan ^a   Lanctôt, Krista L ^b   Khan, Lyla R ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IMIPRAMINE; METHYLPHENIDATE; MIRTAZAPINE; NEUROLEPTIC AGENT; NORADRENALIN; PINDOLOL; PLACEBO; PROPRANOLOL; PSYCHOSTIMULANT AGENT; REBOXETINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CEREBROSPINAL FLUID; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; HUMAN; MENTAL DISEASE; NERVE CELL DEGENERATION; NEUROBIOLOGY; NEUROPATHOLOGY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOSIS; RECEPTOR SENSITIVITY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 3242708372     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.16.3.261     Document Type: Review

References (149)

1. Fratiglioni L, De Ronchi D, Aguero-Torres H: Worldwide prevalence and incidence of dementia. Drugs Aging 1999; 15:365-375
2. Fillit HM: The pharmacoeconomics of Alzheimer's disease. Am J Manag Care 2000; 6(22 suppl):S1139-S1144; discussion S1145-S1138
3. Evans DA, Funkenstein HH, Albert MS, et al: Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989; 262:2551-2556
4. Raskind MA: Geriatric psychopharmacology: management of late-life depression and the noncognitive behavioral disturbances of Alzheimer's disease. Psychiatr Clin North Am 1993; 16:815-827
5. Teri L, Rabins P, Whitehouse P, et al: Management of behavior disturbance in Alzheimer disease: current knowledge and future directions. Alzheimer Dis Assoc Disord 1992; 6:77-88
6. Reisberg B, Borenstein J, Salob SP, et al: Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48(May suppl):9-15
7. Gilley DW, Whalen ME, Wilson RS, et al: Hallucinations and associated factors in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1991; 3:371-376
8. Rabins PV, Mace NL, Lucas MJ: The impact of dementia on the family. JAMA 1982; 248:333-335
9. Nagaratnam N, Lewis-Jones M, Scott D, et al: Behavioral and psychiatric manifestations in dementia patients in a community: caregiver burden and outcome. Alzheimer Dis Assoc Disord 1998; 12:330-334
10. Stoppe G, Brandt CA, Staedt JH: Behavioural problems associated with dementia: the role of newer antipsychotics. Drugs Aging 1999; 14:41-54
11. Mega MS, Cummings JL, Fiorello T, et al: The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46:130-135
12. Petrie W, Lawson E, Hollender M: Violence in geriatric patients. JAMA 1982; 248:443-444
13. Gaspar D: Hollymoor Hospital Dementia Service: analysis of outcome of 230 consecutive referrals to a psychiatric-hospital dementia service. Lancet 1980; 1:1401-1405
14. Hebert R, Dubois MF, Wolfson C, et al: Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci 2001; 56:M693-M699
15. Kunik ME, Yudofsky SC, Silver JM, et al: Pharmacologic approach to management of agitation associated with dementia. J Clin Psychiatry 1994; 55(Feb suppl):13-17
16. Cohen-Mansfield J, Billig N: Agitated behaviors in the elderly, I: a conceptual review. J Am Geriatr Soc 1986; 34:711-721
17. Gleason RP, Schneider LS: Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry 1990; 51:115-118
18. Ryden MB: Aggressive behavior in persons with dementia who live in the community. Alzheimer Dis Assoc Disord 1988; 2:342-355
19. Herrmann N: Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci 2001; 28(suppl 1):S96-S107
20. Yeager BF, Farnett LE, Ruzicka SA: Management of the behavioral manifestations of dementia. Arch Intern Med 1995; 155:250-260
21. Treatment of agitation in older persons with dementia: the expert consensus panel for agitation in dementia. Postgrad Med Special Issue 1998, pp 1-88
22. Lantz MS, Louis A, Lowenstein G, et al: A longitudinal study of psychotropic prescriptions in a teaching nursing home. Am J Psychiatry 1990; 147:1637-1639
23. Avorn J, Dreyer P, Connelly K, et al: Use of psychoactive medication and the quality of care in rest homes: findings and policy implications of a statewide study. N Engl J Med 1989; 320:227-232
24. Gurwitz JH, Soumerai SB, Avorn J: Improving medication prescribing and utilization in the nursing home. J Am Geriatr Soc 1990; 38:542-552
25. Hesse KA, Driscoll A, Jacobson S: Neuroleptic prescriptions for acutely ill geriatric patients. Arch Intern Med 1993; 153:2581-2587
26. Beers MH, Ouslander JG, Rollingher I, et al: Explicit criteria for determining inappropriate medication use in nursing home residents: UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151:1825-1832
27. Semla TP, Palla K, Poddig B, et al: Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents. J Am Geriatr Soc 1994; 42:648-652
28. Dodds MJ: Pre- and post-OBRA '87 psychoactive drug use in long-term care facilities. J Long Term Care Adm 1996; 24:17-22
29. Zayas EM, Grossberg GT: Treating the agitated Alzheimer patient. J Clin Psychiatry 1996; 57(suppl 7):46-51; discussion 52-44
30. Lanctôt KL, Bowles SK, Herrmann N, et al: Drugs mimicking dementia: dementia symptoms associated with psychotropic drugs in institutionalised cognitively impaired patients. CNS Drugs 2000; 14:381-390
31. Lanctôt KL, Best TS, Mittmann N, et al: Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59:550-561; quiz 562-553
32. Schneider LS, Pollock VE, Lyness SA: A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38:553-563
33. Herrmann N, Lanctôt KL: The management of behavioral disturbances in dementia: the role of serotonergic therapies. IDrugs 1998; 1:214-220
34. Lanctôt KL, Herrmann N, Mazzotta P: Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2001; 13:5-21
35. Coull JT: Pharmacological manipulations of the alpha 2-noradrenergic system: effects on cognition. Drugs Aging 1994; 5:116-126
36. Yudofsky SC, Silver JM, Hales RE: Treatment of agitation and aggression, in Textbook of Psychopharmacology. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1998, pp 881-900
37. Redmond D: Studies of the nucleus locus ceruleus in monkeys and hypothesis for neuropsychopharmacology, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer H. New York, Raven Press, 1987, pp 967-975
38. Friedman JI, Adler DN, Davis KL: The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Biol Psychiatry 1999; 46:1243-1252
39. Nestler EJ, Alreja M, Aghajanian GK: Molecular control of locus coeruleus neurotransmission. Biol Psychiatry 1999; 46:1131-1139
40. Beani L, Bianchi C, Giacomelli A, et al: Noradrenaline inhibition of acetylcholine release from guinea-pig brain. Eur J Pharmacol 1978; 48:179-193
41. Vizi ES: Presynaptic modulation of neurochemical transmission. Prog Neurobiol 1979; 12:181-290
42. Vizi ES, Pasztor E: Release of acetylcholine from isolated human cortical slices: inhibitory effect of norepinephrine and phenytoin. Exp Neurol 1981; 73:144-153
43. Bianchi C, Spidalieri G, Guandalini P, et al: Inhibition of acetylcholine outflow from guinea-pig cerebral cortex following locus coeruleus stimulation. Neurosci Lett 1979; 14:97-100
44. Jaim-Etcheverry G, Zieher L: Coexistence of monoamines in peripheral adrenergic neurones, in Co-Transmission. Edited by Cuello A. London, Macmillan, 1982, pp 189-207
45. Murphy DL, Andrews AM, Wichems CH, et al: Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. J Clin Psychiatry 1998; 59(suppl 15):4-12
46. Gillespie DD, Manier DH, Sanders-Bush E, et al: The serotonin/ norepinephrine-link in brain, II: role of serotonin in the regulation of beta adrenoceptors in the low agonist affinity conformation. J Pharmacol Exp Ther 1988; 244:154-159
47. Soderpalm B, Andersson L, Carlsson M, et al: Serotonergic influence on the growth hormone response to clonidine in rat. J Neural Transm 1987; 69:105-114
48. Yamamoto BK, Novotney S: Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 1998; 71:274-280
49. Gresch PJ, Sved AF, Zigmond MJ, et al: Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem 1995; 65:111-116
50. Ferraro L, Tanganelli S, Calo G, et al: Noradrenergic modulation of gamma-aminobutyric acid outflow from the human cerebral cortex. Brain Res 1993; 629:103-108
51. Melia KR, Duman RS: Involvement of corticotropin-releasing factor in chronic stress regulation of the brain noradrenergic system. Proc Natl Acad Sci USA 1991; 88:8382-8386
52. Veith RC, Lewis N, Langohr JI, et al: Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Res 1993; 46:1-8
53. Gerner RH, Yamada T: Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res 1982; 238:298-302
54. Minthon L, Edvinsson L, Gustafson L: Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia. Alzheimer Dis Assoc Disord 1996; 10:197-203
55. de Wied D, van Ree JM: Neuropeptides: animal behaviour and human psychopathology. Eur Arch Psychiatry Neurol Sci 1989; 238:323-331
56. Herrmann N, Lanctôt KL: From transmitters to treatment: the pharmacotherapy of behavioural disturbances in dementia. Can J Psychiatry 1997; 42(suppl 1):51S-64S
57. Lawlor BA, Sunderland T, Mellow AM, et al: Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease: a controlled study. Arch Gen Psychiatry 1989; 46:542-549
58. Bierer LM, Haroutunian V, Gabriel S, et al: Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995; 64:749-760
59. Mann DM, Yates PO, Hawkes J: The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry 1982; 45:113-119
60. Palmer AM, Francis PT, Bowen DM, et al: Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease. Brain Res 1987; 414:365-375
61. Adolfsson R, Gottfries CG, Roos BE, et al: Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 1979; 135:216-223
62. Hoogendijk WJ, Feenstra MG, Botterblom MH, et al: Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann Neurol 1999; 45:82-91
63. Raskind MA, Peskind ER, Halter JB, et al: Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arch Gen Psychiatry 1984; 41:343-346
64. Arai H, Kosaka K, Iizuka R: Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 1984; 43:388-393
65. Francis PT, Palmer AM, Sims NR, et al: Neurochemical studies of early-onset Alzheimer's disease: possible influence on treatment. N Engl J Med 1985; 313:7-11
66. Nazarali AJ, Reynolds GP: Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. Cell Mol Neurobiol 1992; 12:581-587
67. Storga D, Vrecko K, Birkmayer JG, et al: Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci Lett 1996; 203:29-32
68. Mann DM, Yates PO, Marcyniuk B: A comparison of changes in the nucleus basalis and locus caeruleus in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1984; 47:201-203
69. Bondareff W, Mountjoy CQ, Roth M: Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 1982; 32:164-168
70. Hoogendijk WJ, Pool CW, Troost D, et al: Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain 1995; 118(part 1):131-143
71. Gottfries CG, Adolfsson R, Aquilonius SM, et al: Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 1983; 4:261-271
72. Herregodts P, Bruyland M, De Keyser J, et al: Monoaminergic neurotransmitters in Alzheimer's disease: an HPLC study comparing presenile familial and sporadic senile cases. J Neurol Sci 1989; 92:101-116
73. Miller MA, Kolb PE, Leverenz JB, et al: Preservation of noradrenergic neurons in the locus ceruleus that coexpress galanin mRNA in Alzheimer's disease. J Neurochem 1999; 73:2028-2036
74. Iversen LL, Rossor MN, Reynolds GP, et al: Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neurosci Lett 1983; 39:95-100
75. Moll G, Gsell W, Wichart I, et al: Cholinergic and monoaminergic neuromediator systems in DAT: neuropathological and neurochemical findings, in Alzheimer's Disease: Epidemiology, Neuropathy, Neurochemistry, and Clinics. Edited by Maurer K, Riederer P, Beckmann H. New York, Springer Verlag, 1990, pp 235-243
76. Nyberg P, Adolfsson R, Hardy JA, et al: Catecholamine topochemistry in human basal ganglia: comparison between normal and Alzheimer brains. Brain Res 1985; 333:139-142
77. Yates CM, Simpson J, Gordon A, et al: Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res 1983; 280:119-126
78. Matthews KL, Chen CP, Esiri MM, et al: Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry 2002; 51:407-416
79. Förstl H, Burns A, Luthert P, et al: Clinical and neuropathological correlates of depression in Alzheimer's disease. Psychol Med 1992; 22:877-884
80. Perry EK, Tomlinson BE, Blessed G, et al: Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. J Neurol Sci 1981; 51:279-287
81. Tohgi H, Ueno M, Abe T, et al: Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type. J Neural Transm Park Dis Dement Sect 1992; 4:69-77
82. Lawlor BA, Bierer LM, Ryan TM, et al: Plasma 3-methoxy-4- hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease. Biol Psychiatry 1995; 38:185-188
83. Miyata S, Nagata H, Yamao S, et al: Dopamine-beta-hydroxylase activities in serum and cerebrospinal fluid of aged and demented patients. J Neurol Sci 1984; 63:403-409
84. Cross AJ, Crow TJ, Perry EK, et al: Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J (Clin Res Ed) 1981; 282:93-94
85. Elrod R, Peskind ER, DiGiacomo L, et al: Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry 1997; 154:25-30
86. Li PP, Warsh JJ, Godse DD: Rat brain norepinephrine metabolism: substantial clearance through 3,4-dihydroxyphenylethyleneglycol formation. J Neurochem 1983; 41:1065-1071
87. Raskind MA, Peskind ER, Holmes C, et al: Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol Psychiatry 1999; 46:756-765
88. Holmes C, Eisenhofer G, Goldstein DS: Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1994; 653:131-138
89. Peskind ER, Wingerson D, Murray S, et al: Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch Gen Psychiatry 1995; 52:774-782
90. Anand A, Charney DS: Norepinephrine dysfunction in depression. J Clin Psychiatry 2000; 61(suppl 10):16-24
91. Arnsten AF, Steere JC, Hunt RD: The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function: potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53:448-455
92. Chan-Palay V, Asan E: Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989; 287:373-392
93. Torda C: Effects of catecholamines on behavior. J Neurosci Res 1976; 2:193-202
94. Thoa NB, Eichelman B, Richardson JS, et al: 6-Hydroxydopa depletion of brain norepinephrine and the function of aggressive behavior. Science 1972; 178:75-77
95. Geyer MA, Segal DS: Shock-induced aggression: opposite effects of intraventricularly infused dopamine and norepinephrine. Behav Biol 1974; 10:99-104
96. Charney DS, Heninger GR, Sternberg DE, et al: Adrenergic receptor sensitivity in depression: effects of clonidine in depressed patients and healthy subjects. Arch Gen Psychiatry 1982; 39:290-294
97. Gilles C, Ryckaert P, De Mol J, et al: Clonidine-induced growth hormone secretion in elderly patients with senile dementia of the Alzheimer type and major depressive disorder. Psychiatry Res 1989; 27:277-286
98. Checkly S, Corn T, Glass I, et al: Responsiveness of central alpha-2 adrenoceptors in depression, in The Biology of Depression. Edited by Deakin J. London, Gaskell, 1986, pp 100-120
99. Leckman JF, Maas JW, Redmond DE Jr, et al: Effects of oral clonidine on plasma 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) in man: preliminary report. Life Sci 1980; 26:2179-2185
100. Ordway GA, Widdowson PS, Smith KS, et al: Agonist binding to alpha 2-adrenoceptors is elevated in the locus coeruleus from victims of suicide. J Neurochem 1994; 63:617-624
101. Ressler KJ, Nemeroff CB: Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry 1999; 46:1219-1233
102. Abelson JL, Glitz D, Cameron OG, et al: Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 1991; 48:157-162
103. Nutt DJ: Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 2001; 62(suppl 11):22-27; discussion 28
104. Geracioti TD Jr, Baker DG, Ekhator NN, et al: CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry 2001; 158:1227-1230
105. Gerra G, Zaimovic A, Avanzini P, et al: Neurotransmitter-neuroendocrine responses to experimentally induced aggression in humans: influence of personality variable. Psychiatry Res 1997; 66:33-43
106. Haller J, Makara GB, Kruk MR: Catecholaminergic involvement in the control of aggression: hormones, the peripheral sympathetic, and central noradrenergic systems. Neurosci Biobehav Rev 1998; 22:85-97
107. Redmond DE Jr, Katz MM, Maas JW, et al: Cerebrospinal fluid amine metabolites: relationships with behavioral measurements in depressed, manic, and healthy control subjects. Arch Gen Psychiatry 1986; 43:938-947
108. Swann AC, Secunda SK, Koslow SH, et al: Mania: sympathoadrenal function and clinical state. Psychiatry Res 1991; 37:195-205
109. Eichelman B: Neurochemical and psychopharmacologic aspects of aggressive behavior, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer H. New York, Raven Press, 1987, pp 697-704
110. Brown GL, Goodwin FK, Ballenger JC, et al: Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1979; 1:131-139
111. Gerra G, Avanzini P, Zaimovic A, et al: Neurotransmitter and endocrine modulation of aggressive behavior and its components in normal humans. Behav Brain Res 1996; 81:19-24
112. Coccaro EF, Lawrence T, Trestman R, et al: Growth hormone responses to intravenous clonidine challenge correlate with behavioral irritability in psychiatric patients and healthy volunteers. Psychiatry Res 1991; 39:129-139
113. Tsai SJ, Hwang JP, Yang CH, et al: Physical aggression and associated factors in probable Alzheimer disease. Alzheimer Dis Assoc Disord 1996; 10:82-85
114. Ware CJG, Fairburn CG, Hope RA: A community-based study of aggressive behaviour in dementia. Int J Geriatr Psychiatry 1990; 5:337-342
115. Lyketsos CG, Steinberg M, Tschanz JT, et al: Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157:708-714
116. Lee MM, Strauss ME, Dawson DV: Changes in emotional and behavioral symptoms of Alzheimer's disease. Am J Alzheimer Dis Other Demen 2000; 15:176-179
117. Keene J, Hope T, Fairburn CG, et al: Natural history of aggressive behaviour in dementia. Int J Geriatr Psychiatry 1999; 14:541-548
118. Raskind MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord 1994; 8(suppl 3):54-60
119. Lindenmayer JP: The pathophysiology of agitation. J Clin Psychiatry 2000; 61(suppl 14):5-10
120. Margallo-Lana M, Swann A, O'Brien J, et al: Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001; 16:39-44
121. Zweig RM, Ross CA, Hedreen JC, et al: The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 1988; 24:233-242
122. Zubenko GS, Moossy J: Major depression in primary dementia: clinical and neuropathologic correlates. Arch Neurol 1988; 45:1182-1186
123. Hoogendijk WJ, Sommer IE, Pool CW, et al: Lack of association between depression and loss of neurons in the locus coeruleus in Alzheimer disease. Arch Gen Psychiatry 1999; 56:45-51
124. Zubenko GS, Moossy J, Kopp U: Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990; 47:209-214
125. Russo-Neustadt A, Cotman CW: Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients. J Neurosci 1997; 17:5573-5580
126. Brane G, Gottfries CG, Blennow K, et al: Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia. Alzheimer Dis Assoc Disord 1989; 3:148-156
127. Anden NE, Pauksens K, Svensson K: Selective blockade of brain alpha 2-autoreceptors by yohimbine: effects on motor activity and on turnover of noradrenaline and dopamine. J Neural Transm 1982; 55:111-120
128. Peskind ER, Elrod R, Dobie DJ, et al: Cerebrospinal fluid epinephrine in Alzheimer's disease and normal aging. Neuropsychopharmacology 1998; 19:465-471
129. Aarsland D, Cummings JL, Yenner G, et al: Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Am J Psychiatry 1996; 153:243-247
130. Zubenko GS, Moossy J, Martinez AJ, et al: Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991; 48:619-624
131. Förstl H, Burns A, Levy R, et al: Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease. Br J Psychiatry 1994; 165:53-59
132. Yudofsky S, Silver J, Schneider S: Pharmacologic treatment of aggression. Psychiatr Annals 1987; 27:397-407
133. Greendyke RM, Kanter DR, Schuster DB, et al: Propranolol treatment of assaultive patients with organic brain disease: a double-blind crossover, placebo-controlled study. J Nerv Ment Dis 1986; 174:290-294
134. Petrie WM, Ban TA: Propranolol in organic agitation (letter). Lancet 1981; 1:324
135. Shankle WR, Nielson KA, Cotman CW: Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord 1995; 9:233-237
136. Yudofsky S, Williams D, Gorman J: Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes. Am J Psychiatry 1981; 138:218-220
137. Weiler PG, Mungas D, Bernick C: Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol 1988; 1:226-230
138. Greendyke RM, Kanter DR: Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry 1986; 47:423-426
139. Silver JM, Yudofsky SC, Kogan M, et al: Elevation of thioridazine plasma levels by propranolol. Am J Psychiatry 1986; 143:1290-1292
140. Stanford SC: Central noradrenergic neurones and stress. Pharmacol Ther 1995; 68:297-242
141. Reifler BV, Teri L, Raskind M, et al: Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 1989; 146:45-49
142. Peisah C, Brodaty H: Practical guidelines for the treatment of behavioural complications of dementia. Med J Aust 1994; 161:558-563
143. de Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57(suppl 4):19-25
144. Raji MA, Brady SR: Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Ann Pharmacother 2001; 35:1024-1027
145. Maletta GJ, Winegarden T: Reversal of anorexia by methylphenidate in apathetic, severely demented nursing home patients. Am J Geriatr Psychiatry 1993; 1:234-243
146. Kaufmann MW, Cassem NH, Murray GB, et al: Use of psychostimulants in medically ill patients with neurological disease and major depression. Can J Psychiatry 1984; 29:46-49
147. Branconnier RJ, Cole JO: The therapeutic role of methylphenidate in senile organic brain syndrome. Proc Annu Meet Am Psychopathol Assoc 1980; 69:183-196
148. Galynker I, Ieronimo C, Miner C, et al: Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci 1997; 9:231-239
149. D'Amato RJ, Zweig RM, Whitehouse PJ, et al: Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1987; 22:229-236